An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Public ClinicalTrials.gov record NCT03704077. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Active-Controlled, Open-Label, Phase 2 Clinical Trial of BMS-986213, in Combination With Various Standard-of-Care Therapeutic Regimens, in Participants With Recurrent, Locally Advanced, or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction (GEJ) Adenocarcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the effectiveness of relatlimab plus nivolumab, alone or in combination with various standard-of-care treatments in participants with gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma that has come back or spread to other places in the body after prior therapy.
Study identification
- NCT ID
- NCT03704077
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- Not listed
Conditions and interventions
Interventions
- Relatlimab + Nivolumab Biological
- Nivolumab Biological
- Paclitaxel Drug
- Ramucirumab Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2019 (Estimated)
- Primary completion
- Feb 27, 2022 (Estimated)
- Completion
- Sep 30, 2024 (Estimated)
- Last update posted
- May 19, 2020
2019 – 2024
United States locations
- U.S. sites
- 20
- U.S. states
- 13
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution | Daphne | Alabama | 36526 | — |
| Local Institution | Bakersfield | California | 93309 | — |
| Local Institution | Fullerton | California | 92835 | — |
| Local Institution | Los Angeles | California | 90095 | — |
| Local Institution | Redondo Beach | California | 90277 | — |
| Local Institution | Santa Barbara | California | 93105 | — |
| Local Institution | Aurora | Colorado | 80045 | — |
| Local Institution | Lakewood | Colorado | 80228 | — |
| Local Institution | Miami | Florida | 33176 | — |
| Local Institution | Tampa | Florida | 33612 | — |
| Local Institution | Marietta | Georgia | 30060 | — |
| Local Institution | Boston | Massachusetts | 02215 | — |
| Local Institution | St Louis | Missouri | 63110 | — |
| Local Institution | New Brunswick | New Jersey | 08009 | — |
| Local Institution | Chapel Hill | North Carolina | 27599 | — |
| Local Institution | Charlotte | North Carolina | 28204 | — |
| Local Institution | Fargo | North Dakota | 58102 | — |
| Local Institution | Allentown | Pennsylvania | 18103 | — |
| Local Institution | Sioux Falls | South Dakota | 57104 | — |
| Local Institution | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 64 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03704077, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 19, 2020 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03704077 live on ClinicalTrials.gov.